A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, multicenter, blinded Phase I/II, investigator and
subject-blinded study of the safety of escalating doses of ocrelizumab in combination with
MTX in subjects with moderate to severe RA